en

Sign up
Investments involve risks and are not suitable for all investors.

MC

662

+1.39%↑

ALV

261.5

+0.93%↑

SAF

202.5

+1.25%↑

BBVA

10.03

+0.05%↑

BN

58.98

+1.17%↑

MC

662

+1.39%↑

ALV

261.5

+0.93%↑

SAF

202.5

+1.25%↑

BBVA

10.03

+0.05%↑

BN

58.98

+1.17%↑

MC

662

+1.39%↑

ALV

261.5

+0.93%↑

SAF

202.5

+1.25%↑

BBVA

10.03

+0.05%↑

BN

58.98

+1.17%↑

MC

662

+1.39%↑

ALV

261.5

+0.93%↑

SAF

202.5

+1.25%↑

BBVA

10.03

+0.05%↑

BN

58.98

+1.17%↑

MC

662

+1.39%↑

ALV

261.5

+0.93%↑

SAF

202.5

+1.25%↑

BBVA

10.03

+0.05%↑

BN

58.98

+1.17%↑

Home・Stock List・Bayer AG
Search

Bayer AG

Closed

Sector Finance

27.415 -0.76

Neutral

Price update 26 Jul 2024, 15:29 UTC

BuySell

Overview

Share price change

24h

Current

Min

27.175

Max

27.625

Key metrics

By Trading Economics

Income

663M

2B

Sales

1.9B

14B

P/E

Sector Avg

30.9

20.407

EPS

2.82

Profit margin

14.524

EBITDA

1.3B

4.4B

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

+10.42 upside

Dividends

By Dow Jones

Next Earnings

6 Aug 2024

Market Stats

By TradingEconomics

Market Cap

192M

26B

Previous open

28.18

Previous close

27.415

News Sentiment

By Acuity

53%

47%

342 / 459 Finance

Technical Score

By Trading Central

Confidence

Strong Bullish Evidence

26.935 / 27.53 Support & Resistance

Bayer AG Chart

Related News

14 May 2024, 13:21 UTC

Earnings

Bayer Plans More Job Cuts in Push for Fewer Bosses -- Update

DJ

Read

14 May 2024, 06:13 UTC

Earnings

Bayer Net Profit Falls on Lower Sales, Currency Headwinds

DJ

Read

2 May 2024, 11:10 UTC

Major Market Movers

Bayer Shares Surge After Monsanto Appeal Win

DJ

Read

5 Mar 2024, 09:09 UTC

Earnings
Acquisitions, Mergers, Takeovers

Bayer Decides Against Splitting Into Separate Units for Now -- 2nd Update

DJ

Read

12 Jul 2024, 07:05 UTC

Market Talk

Bayer's Cost-Savings and Cash Delivery Key Focus for 2Q -- Market Talk

DJ

Read

5 Jun 2024, 09:57 UTC

Hot Stocks

Stocks to Watch Wednesday: CrowdStrike, HPE, Dollar Tree -- WSJ

DJ

Read

14 May 2024, 11:00 UTC

Market Talk
Earnings

Bayer Earnings Show Progression on Turnaround Strategy -- Market Talk

DJ

Read

14 May 2024, 05:34 UTC

Earnings

Bayer Backs 2024 Currency-Adjusted Outlook

DJ

Read

14 May 2024, 05:32 UTC

Earnings

Bayer: Analysts Saw 1Q Ebitda Before Special Items at EUR4.15B

DJ

Read

14 May 2024, 05:32 UTC

Earnings

Bayer 1Q Ebitda Before Special Items EUR4.41B

DJ

Read

14 May 2024, 05:32 UTC

Earnings

Bayer 1Q EPS EUR2.04

DJ

Read

14 May 2024, 05:32 UTC

Earnings

Bayer: Analysts Saw 1Q Sales at EUR14.08B

DJ

Read

14 May 2024, 05:32 UTC

Earnings

Bayer 1Q Sales EUR13.77B

DJ

Read

14 May 2024, 05:31 UTC

Earnings

Bayer 1Q EBIT EUR3.09B

DJ

Read

14 May 2024, 05:31 UTC

Earnings

Bayer: Analysts Saw 1Q Net Pft at EUR1.73B

DJ

Read

14 May 2024, 05:31 UTC

Earnings

Bayer 1Q Net Pft EUR2B

DJ

Read

13 May 2024, 13:26 UTC

Earnings

Bayer Investors Brace for Long Turnaround -- Talking Markets

DJ

Read

15 Apr 2024, 14:01 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Bayer's Consumer-Healthcare Unit Remains Attractive Acquisition Target -- Market Talk

DJ

Read

15 Apr 2024, 13:39 UTC

Market Talk

Bayer's Debt Reduction, Litigation and Drug Pipeline in Focus at 1Q Results -- Market Talk

DJ

Read

22 Mar 2024, 04:01 UTC

Top News

One CEO's Radical Fix for Corporate Troubles: Purge the Bosses -- WSJ -2-

DJ

Read

22 Mar 2024, 04:01 UTC

Top News

One CEO's Radical Fix for Corporate Troubles: Purge the Bosses -- WSJ

DJ

Read

5 Mar 2024, 10:23 UTC

Earnings

Bayer CEO Was Speaking on Call After Earnings

DJ

Read

5 Mar 2024, 10:19 UTC

Market Talk
Earnings

Bayer's EPS Guidance Implies Consensus Downgrades -- Market Talk

DJ

Read

5 Mar 2024, 09:55 UTC

Market Talk
Earnings

Bayer's 2024 Guidance Is Below Expectations -- Market Talk

DJ

Read

5 Mar 2024, 09:44 UTC

Earnings

Bayer CEO: Time it Takes For Major Structural Change is Time We Don't Have, Need to Focus on Challenges

DJ

Read

5 Mar 2024, 09:44 UTC

Earnings

Bayer CEO: There Has Been Calls From Major Shareholders For Break-Up, But They Understand Associated Drawbacks

DJ

Read

5 Mar 2024, 08:52 UTC

Earnings

Bayer CEO: Exploring All Avenues to Remove Litigation Completely

DJ

Read

5 Mar 2024, 08:51 UTC

Earnings

Bayer CEO: Strategy of Defence Against Litigation is Not Enough

DJ

Read

5 Mar 2024, 08:44 UTC

Earnings

Bayer CEO: Need Total Focus on Overcoming Challenges

DJ

Read

5 Mar 2024, 08:44 UTC

Earnings

Bayer CEO: Separation of Consumer Health Would Remove Steady Cash Flowing Business, Valutions Not Great

DJ

Read

Peer Comparison

Price change

Bayer AG Forecast

Price Target

By TipRanks

10.42% upside

12 Months Forecast

Average 30.4 EUR  10.42%

High 34 EUR

Low 28 EUR

Based on 11 Wall Street analysts offering 12 month price targets forBayer AG - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

11 ratings

1

Buy

10

Hold

0

Sell

Based on 11 analysts giving stock ratings to Bayer AG - Dist in the past 3 months.

Technical Score

By Trading Central

26.935 / 27.53Support & Resistance

Short Term

Strong Bullish Evidence

Recent bullish events outweigh bearish events.

Intermediate Term

Strong Bullish Evidence

Recent bullish events outweigh bearish events.

Long Term

Weak Bullish Evidence

Recent bullish events outweigh bearish events.

Sentiment

By Acuity

342 / 459 Finance

News Sentiment

Bearish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

EBITDA

Operating profit

$

About Bayer AG

Bayer AG is a German-based life science company. The Company's segments are Pharmaceuticals, Consumer Health, Crop Science and Animal Health. The Pharmaceuticals segment focuses on researching, developing and marketing prescription products and specialty therapeutics especially in the areas of cardiology, oncology, gynecology, hematology and ophthalmology, as well as radiopharmacology and others. The company is focusing on their oncology platform o Targeted Alpha Therapies for treating prostate cancer. Th Consumer Health segment develops, produces and markets nonprescription over-the-counter products in the dermatology, dietary supplement, analgesic, gastrointestinal, cold, allergy, sinus and flu, foot care and sun protection categories, among others. The Crop Science segment researches, develops and markets crop protection solutions and seeds, and includes the subsidiary Monsanto. The Animal Health segment is engaged in the development, production and marketing of prescription and non

Other stocks from the sector

MC

LVMH Moet Hennessy Louis Vuitton SE.

662

↑ +1.39%

ALV

Allianz SE

261.5

↑ +0.93%

SAF

Safran SA.

202.5

↑ +1.25%

BBVA

Banco Bilbao Vizcaya Argentaria SA

10.03

↑ +0.05%

BN

Danone SA

58.98

↑ +1.17%